<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a diverse group of disorders characterized by disorderly and ineffective hematopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>Patients suffer morbidity from associated cytopenias that result in an increased risk of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, transfusion-dependent <z:hpo ids='HP_0001903'>anemia</z:hpo>, and <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Despite the variable risk of transformation to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, the majority of <z:hpo ids='HP_0011420'>deaths</z:hpo> are due to <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>No truly effective treatment exists for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and therapy usually focuses on reducing or preventing complications of the disease </plain></SENT>
<SENT sid="4" pm="."><plain>Identification of potential cellular and molecular targets, such as epigenetic modification, has led to novel therapeutic approaches in recent years </plain></SENT>
<SENT sid="5" pm="."><plain>An increasing number of diagnostic markers, prognostic parameters, and therapeutic strategies are available and becoming widely accepted </plain></SENT>
</text></document>